A5056918526- SARS-CoV-2 and COVID-19 Research
- Trypanosoma species research and implications
- Research on Leishmaniasis Studies
- vaccines and immunoinformatics approaches
- Parasites and Host Interactions
- Animal Virus Infections Studies
- Bacillus and Francisella bacterial research
- Helminth infection and control
- Parasite Biology and Host Interactions
- Viral Infections and Immunology Research
- Advanced biosensing and bioanalysis techniques
- Transgenic Plants and Applications
- Viral gastroenteritis research and epidemiology
- Mosquito-borne diseases and control
- Synthesis and Biological Evaluation
- RNA and protein synthesis mechanisms
- Vaccine Coverage and Hesitancy
- Insect symbiosis and bacterial influences
- SARS-CoV-2 detection and testing
- IL-33, ST2, and ILC Pathways
- Studies on Chitinases and Chitosanases
- Viral Infections and Vectors
- Aquaculture disease management and microbiota
- Zebrafish Biomedical Research Applications
- Autoimmune and Inflammatory Disorders Research
Baylor College of Medicine
2016-2025
Texas Children's Hospital
2016-2025
Wageningen University & Research
2019-2025
Bipar
2024
Center for Children
2021
Sabin Vaccine Institute
2015-2017
University of Houston
2015
There is an urgent need for accessible and low-cost COVID-19 vaccine suitable low- middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia pastoris), as candidate against COVID-19. After introducing two modifications into wild-type RBD gene to reduce yeast-derived hyperglycosylation improve stability during protein expression, show that recombinant RBD219-N1C1, equivalent (RBD219-WT) vitro...
Chagas disease affects 6 to 7 million people worldwide, resulting in significant burdens and health care costs countries of endemicity. Chemotherapeutic treatment is restricted two parasiticidal drugs, benznidazole nifurtimox. Both drugs are highly effective during acute but only minimally chronic fraught with adverse clinical effects. In experimental models, vaccines can be used induce parasite-specific balanced TH1/TH2 immune responses that effectively reduce parasite associated...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed more than 4 million humans globally, but there is no bona fide Food and Drug Administration-approved drug-like molecule to impede the COVID-19 pandemic. The sluggish pace of traditional therapeutic discovery poorly suited producing targeted treatments against rapidly evolving viruses. Here, we used an affinity-based screen billion DNA-encoded molecules en masse identify a potent class virus-specific inhibitors SARS-CoV-2...
SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple manufacturers to address the global vaccine equity gap, and need for low-cost, easy scale, safe, effective COVID-19 vaccines. In this paper, we report on generation of receptor-binding domain RBD203-N1 yeast expression construct, which produces a recombinant capable eliciting robust immune response protection in mice against challenge infections. The antigen was expressed Pichia pastoris X33. After fermentation at...
We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM that recently received emergency use authorization by Drugs Controller General of India. compared immune response vaccinated RBD/alum + CpG. also evaluated immunized boosted RBD/alum. Mice were twice intramuscularly at 21-day interval. Compared two doses /alum formulation,...
Introduction The development of a yeast-expressed recombinant protein-based vaccine technology co-developed with LMIC producers and suitable as COVID-19 for global access is described. proof-of-concept developing SARS-CoV-2 spike protein receptor-binding domain (RBD) antigen yeast-derived described.Areas Covered Genetic Engineering: strategy presented the design genetic modification used during cloning expression in yeast system. Process Assay Development: A summary how scalable,...
Chagas disease (CD) (American trypanosomiasis caused by Trypanosoma cruzi) is a parasitic endemic in 21 countries South America, with increasing global spread. When administered late the infection, current antiparasitic drugs do not prevent onset of cardiac illness leading to chronic Chagasic cardiomyopathy. Therefore, new therapeutic vaccines or immunotherapies are under development using multiple platforms. In this study, we assessed feasibility developing an mRNA-based CD vaccine...
A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of to significantly reduce parasite burden Trypanosoma cruzi in humans, either as a standalone product or combination with conventional chemotherapy. Vaccination mice Tc24 formulated monophosphoryl-lipid (MPLA) adjuvant results Th1 skewed immune response elevated IgG2a and IFNγ levels statistically significant decrease parasitemia following T. challenge....
Chagas disease, caused by the parasite Trypanosoma cruzi, develops into chronic Chagas' cardiomyopathy in ~30% of infected individuals, characterized conduction disorders, arrhythmias, heart failure, and even sudden cardiac death. Current anti-parasitic treatments are plagued significant side effects poor efficacy phase disease; thus, there is a pressing need for new treatment options. A therapeutic vaccine could bolster protective TH1-mediated immune response, thereby slowing or halting...
Tc24 is a Trypanosoma cruzi-derived flagellar protein that, when formulated with TLR-4 agonist adjuvant, induces balanced immune response in mice, elevating IgG2a antibody titers and IFN-γ levels. Furthermore, vaccination the recombinant can reduce parasite levels improve survival during acute infection. Although some mRNA vaccines have been proven to elicit stronger than vaccines, they not used against T. cruzi. This work evaluates immunogenicity of heterologous prime/boost regimen using...
Introduction Chagas disease, caused by chronic infection with the protozoan parasite Trypanosoma cruzi, affects 6-7 million people worldwide. The major clinical manifestation of disease is Chagasic cardiomyopathy (CCC), which encompasses a spectrum symptoms including arrhythmias, hypertrophy, dilated cardiomyopathy, heart failure, and sudden death. Current treatment limited to two antiparasitic drugs, benznidazole (BNZ) nifurtimox, but both have efficacy halt progression CCC. We developed...
Ascaris lumbricoides (roundworm) is the most common helminth infection globally and a cause of lifelong morbidity that may include allergic airway disease, an asthma phenotype. We hypothesize larval migration through lungs leads to persistent hyperresponsiveness (AHR) type 2 inflammatory lung pathology despite resolution resembles disease. Mice were infected with by oral gavage. Lung AHR was measured plethysmography histopathology hematoxylin eosin (H&E) periodic acid-Schiff (PAS) stains,...
Abstract Chagas disease resulting from Trypanosoma cruzi infection leads to a silent, long-lasting chronic neglected tropical affecting the poorest and underserved populations around world. Antiparasitic treatment with benznidazole does not prevent progression or death in patients established cardiac disease. Our consortium is developing therapeutic vaccine based on T. flagellar—derived antigen Tc24-C4 formulated Toll-like receptor 4 agonist adjuvant, complement existing chemotherapy improve...
Over 400 million people living in the world's poorest developing nations are infected with hookworms, mostly of genus Necator americanus. A bivalent human hookworm vaccine composed americanus Glutathione S-Transferase-1 (Na-GST-1) and Aspartic Protease-1 (Na-APR-1 (M74)) is currently under development by Sabin Vaccine Institute Product Development Partnership (Sabin PDP). Both monovalent vaccines Phase 1 trials. Na-GST-1 Na-APR-1 antigens expressed as recombinant proteins. While was found to...
Ascariasis remains the most common helminth infection in humans. As an alternative or complementary approach to global deworming, a pan-anthelminthic vaccine is under development targeting Ascaris, hookworm, and Trichuris infections. As16 As14 have previously been described as two genetically related proteins from Ascaris suum that induced protective immunity mice when formulated with cholera toxin B subunit (CTB) adjuvant, but exact mechanism was not well understood.As16 were highly...
Background Ascaris lumbricoides is one of the three major soil-transmitted gastrointestinal helminths (STHs) that infect more than 440 million people in world, ranking this neglected tropical disease among most common afflictions living poverty. Children infected with roundworm suffer from malnutrition, growth stunting as well cognitive and intellectual deficits. An effective vaccine urgently needed to complement anthelmintic deworming a better approach control helminth infections. As37 an...
Abstract There is an urgent need for accessible and low-cost COVID-19 vaccine suitable low- middle-income countries. Here we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast ( Pichia pastoris ), as candidate against COVID-19. After introducing two modifications into wild-type RBD gene to reduce yeast-derived hyperglycosylation improve stability during protein expression, show that recombinant RBD219-N1C1, equivalent...
Zebrafishes represent a proven model for human diseases and systems biology, exhibiting physiological genetic similarities having innate adaptive immune systems. However, they are underexplored vaccinology, vaccine development, testing. Here we summarize gaps challenges.
Background The antigen Na -GST-1, expressed by the hookworm Necator americanus , plays crucial biochemical roles in parasite survival. This study explores development of mRNA vaccine candidates based on building success recombinant -GST-1 (r -GST-1) protein, currently assessed as a subunit candidate, which has shown promise preclinical and clinical studies. Methodology/findings By leveraging flexible design RNA vaccines protein intracellular trafficking signal sequences, we developed three...
Soil-transmitted helminth (STH) infections rank among the most prevalent communicable diseases of humans, yet detection these parasites is mostly restricted to identifying active infection through fecal examinations. Currently, there are no commercial diagnostic tools identify a prior whipworm or hookworm exposure, and few serological assays for roundworm have not been well validated crossreactivity in humans. Such restrictions limit range scientific clinical questions that surround STH...
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects millions globally. Despite treatment options in acute phase, most infections progress to a chronic indeterminate form or develop severe cardiac/gastrointestinal complications. Understanding immune response is crucial for development of vaccines and more efficient drugs control. This work investigates T. cruzi H1 K68 strain infection female BALB/c C57BL/6 mice characterize differences Tfh B cell responses that may be...
Chronic infection with the protozoal parasite Trypanosoma cruzi leads to a progressive cardiac disease, known as chronic Chagasic cardiomyopathy (CCC). A new therapeutic Chagas disease vaccine is in development augment existing antiparasitic chemotherapy drugs.We report on our current understanding of underlying immunologic and physiologic mechanisms that lead CCC, including immune escape allow persistence subsequent inflammatory fibrotic processes clinical disease. We design observed...